Universal coverage of IVF: benefits, unintended barriers and lessons from the French model in an international...

France's universal public funding of assisted reproductive technology represents a major achievement for reproductive equity. By removing financial barriers, it has broadened access to fertility care while ensuring high standards of safety, traceability and clinical outcomes. Public oversight has further strengthened quality assurance through mandatory ISO 15189 accreditation of IVF laboratories and implementation of EU Tissues and Cells regulations. However, expanding entitlement without a proportional reinforcement of resources, staffing, laboratory capacity, reimbursement levels and donor availability has generated structural tensions. Complex regulatory demands impose substantial administrative and financial burdens on centres, diverting time and investment from patient care. Inadequate funding of IVF units, persistent shortages of gamete donors and rising overhead costs have created waiting lists and inequitable delays. France also prohibits certain internationally accepted procedures, such as preimplantation genetic testing for aneuploidies, restricting clinical autonomy and patient choice. These unintended effects risk undermining the very principles of universality, equity and quality that underpin France's policy. Comparison with Belgium, the UK, Spain and Quebec, systems that pair broad coverage with more flexible regulation or reimbursement, helps identify ways to rebalance access, oversight and innovation. We propose pragmatic policy adjustments, including realistic reimbursement of laboratory costs, streamlined accreditation, targeted donor-recruitment incentives and evidence-based reconsideration of prohibited techniques.